CytomX Therapeutics to Announce First Quarter 2021 Financial Results on May 6, 2021
29 Abril 2021 - 7:00AM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage
oncology-focused biopharmaceutical company pioneering a novel class
of investigational conditionally activated antibody therapeutics
based on its Probody® technology platform, today announced that it
will report first quarter 2021 financial results on Thursday,
May 6, 2021, after the close of U.S. markets. Following the
announcement, the Company will host a conference call and webcast
at 5:00 p.m. ET / 2:00 p.m. PT to discuss the
results and provide a corporate update.
Participants may access the live webcast of the
conference call from the Events and Presentations page of CytomX’s
website at www.cytomx.com. An archived replay of the webcast
will be available on the Company's website until May 13, 2021.
Audio Conference Call:
|
U.S. Dial-in
Number: |
(877)
809-6037 |
|
|
|
|
International Dial-in Number: |
(615) 247-0221 |
|
|
|
|
Conference ID: |
5397530 |
About CytomX
TherapeuticsCytomX is a clinical-stage, oncology-focused
biopharmaceutical company with a vision of transforming lives with
safer, more effective therapies. We are developing a novel class of
investigational conditionally activated antibody therapeutics,
based on our Probody® technology platform, for the treatment of
cancer. CytomX has strategic drug discovery and development
collaborations with AbbVie, Amgen, Astellas, and Bristol Myers
Squibb.
Probody therapeutics are conditionally activated
antibodies designed to remain inactive until they are activated by
proteases in the tumor microenvironment. As a result, Probody
therapeutics are intended to bind selectively to tumors and
decrease binding to healthy tissue, to minimize toxicity and
potentially create safer, more effective therapies. As leaders in
the field, our innovative technology is designed to turn previously
undruggable targets into druggable targets and to enable more
effective combination therapies. CytomX and its partners, comprised
of leading biotechnology and pharmaceutical companies, have
developed a robust pipeline of potential first-in-class therapeutic
candidates against novel, difficult to drug targets and potential
best-in-class immunotherapeutic candidates against clinically
validated targets. The CytomX clinical-stage pipeline comprises
five assets, four of which are in Phase 2 clinical studies.
First-in-class product candidates against previously undruggable
targets include a CD166-targeting conditionally activated
antibody-drug conjugate wholly owned by CytomX (praluzatamab
ravtansine, CX-2009) and a CD71-targeting conditionally activated
antibody-drug conjugate partnered with AbbVie (CX-2029). CD166 and
CD71 are among cancer targets that are considered to be
inaccessible to conventional antibody-drug conjugates due to their
presence on many healthy tissues. The CytomX clinical-stage
pipeline also includes cancer immunotherapeutic candidates against
validated targets such as the CTLA-4-targeting Probodies,
BMS-986249 and BMS-986288, partnered with Bristol Myers Squibb, and
our wholly-owned conditionally activated anti-PD-L1 antibody,
pacmilimab (CX-072). For additional information about CytomX
Therapeutics, visit www.cytomx.com and follow us on LinkedIn and
Twitter.
CytomX Therapeutics Forward-Looking
StatementsThis press release includes forward-looking
statements. Such forward-looking statements involve known and
unknown risks, uncertainties and other important factors that are
difficult to predict, may be beyond our control, and may cause the
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied in such statements. Accordingly, you should
not rely on any of these forward-looking statements, including
those relating to the potential benefits, safety and efficacy or
progress of CytomX’s or any of its collaborative partners’ product
candidates, including praluzatamab ravtansine (CX-2009), CX-2029,
BMS-986249, BMS-986288, and pacmilimab (CX-072), the potential
benefits or applications of CytomX’s Probody platform technology,
CytomX’s ability to develop and advance product candidates into and
successfully complete clinical trials, including the ongoing and
planned clinical trials of praluzatamab ravtansine, CX-2029,
BMS-986249, BMS-986288, and pacmilimab (CX-072), and the timing of
the commencement of clinical trials and other development
milestones. Risks and uncertainties that contribute to the
uncertain nature of the forward-looking statements include: the
unproven nature of CytomX’s novel Probody Platform technology;
CytomX’s clinical trial product candidates are in the initial
stages of clinical development and its other product candidates are
currently in preclinical development, and the process by which
preclinical and clinical development could potentially lead to an
approved product is long and subject to significant risks and
uncertainties, including the risk that the COVID-19 worldwide
pandemic may continue to negatively impact the business, research
and clinical operations of CytomX or its partners, including the
development of preclinical drug candidates due to delays in and
disruption of research activities and the development of clinical
drug candidates due to delays in or disruption of clinical trials,
including impacts on the enrollment of patients in clinical trials
or other clinical trial disruptions; the possibility that the
results of early clinical trials may not be predictive of future
results; the possibility that CytomX’s clinical trials will not be
successful; the possibility that current preclinical research may
not result in additional product candidates; CytomX’s dependence on
the success of praluzatamab ravtansine, CX-2029, BMS-986249,
BMS-986288, and pacmilimab (CX-072); CytomX’s reliance on third
parties for the manufacture of the company’s product candidates;
and possible regulatory developments in the United
States and foreign countries. Additional applicable risks and
uncertainties include those relating to our preclinical research
and development, clinical development, and other risks identified
under the heading "Risk Factors" included in CytomX’s Annual Report
on Form 10-K filed with the SEC on February 24,
2021. The forward-looking statements contained in this press
release are based on information currently available to CytomX and
speak only as of the date on which they are made. CytomX does not
undertake and specifically disclaims any obligation to update any
forward-looking statements, whether as a result of any new
information, future events, changed circumstances or otherwise.
Probody is a U.S. registered trademark of CytomX Therapeutics,
Inc.
CytomX Contact:Chau Cheng, PhD
MBAVP, Investor Relations & Corp.
Communicationsccheng@cytomx.comDirect: (650) 273-4999
Investor and Media
Contact:Stern Investor RelationsStephanie
Ascherstephanie.ascher@sternir.com212-362-1200
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024